ASSESSMENT OF THERAPEUTIC EFFICACY OF JOINT USE
OF SOME ANTHRACYCLINE ANTIBIOTICS AND ANTIOXIDANTS 

Minnigaleeva Sariet Dzhangaryevna, Assistant, sub-department of human physiology, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), smin2005@yandex.ru
Mikulyak Nadezhda Ivanovna, Doctor of medical science, professor, head of sub-department of human physiology, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), normphys@mail.ru
Magdeev Ruslan Ramisovich, Postgraduate student, Medical Institute, Penza State University
(40 Krasnaya street, Penza, Russia), magdeev2008@rambler.ru
Kinzirskiy Aleksandr Sergeevich, Doctor of medical sciences, professor, chief researcher, Institute of physiologically active substances of the Russian Academy of Sciences
(1 Severny lane, Chernogolovka, Moscow region, Russia), akinz@inbox.ru
Mikulyak Artur Ivanovich, Cardiosurgeon, Federal center of cardio-vascular surgery
(6 Stasova street, Penza, Russia), mikulyak.artur@gmail.com
Solomanina Ol'ga Olegovna, Candidate of medical sciences, associate professor, sub-department of human physiology, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), normphys@mail.ru

612.1.616-006-085

Background. The article aims at studying the impact of antioxidants such as mexidol, probucol and α-tocopherol on the specific efficacy of cytostatic therapy.
Materials and methods. The Lewis lung carcinoma (LLC) – a syngeneic tumor system obtained from a bank of tumor strains (Blokhin Cancer Research Center) was used as a model of tumor growth. LLC tumor tissues were transplanted intramuscularly in the left thigh of animals in the amount of 1 × 106 cells in Hanks solution ("Biolot" Ltd., Russia). Doxorubicine was introduced at a dose of 4 mg/kg twice in an interval of 120 hours between introductions, starting chemotherapy since the 7-th day after inoculation of LLC strain of C57Bl /6 line into mice. The antitumor effect was evaluated in terms of the index of growth of inhibition of primary tumor mass (TGI).
Results. It was established that the use of antioxidants such as mexidol, probucol, α-tocopherol is safe in terms of its possible effects on tumor growth stimulation. Antitumor efficacy of antibiotics increases with concomitant introduction of daunorubicine, probucol and meksidolom, displaying a decrease in growth rate of primary tumor. Combined use of mexidol, probucol and anthracycline antibiotics increased the antimetastatic effect of antibiotics. These effects are less pronounced after α-tocopherol.
Conclusions. The obtained results show the effectiveness of mexidol, probucol, α-tocopherol with doxorubicine and daunorubicine. Of all the antioxidants used it was only meksidol in combination with doxorubicine that showed the highest rates of anti-metastatic activity.

antitumor effectiveness, anthracycline antibiotics, antioxidants.

1. Menna P., Salvatorelli E., Minotti G. Chem. Res. Toxicol. 2008, vol. 21, no. 5, pp. 978–989.
2. Moiseeva I. Ya., Kotlyarov A. A. Uspekhi sovremennogo estestvoznaniya [Progress of modern natural science]. 2007, no. 2, pp. 87–97.
3. Simbre V. C., Duffy S. A., Dadlani G. H. et al. Paediatr. Drugs. 2005, vol. 7, no. 3, pp. 187–202.
4. Hoppe U. C. Med. Klin. (Munich). 2006, vol. 101, suppl. 1, pp. 31–35.
5. Jensen S. A., Sorensen J. B. Cancer Chemother. Pharmacol. 2006, vol. 58, no. 4, pp. 487–493.
6. Jones R. L., Ewer M. S. Expert Rev. Anticancer Ther. 2006, vol. 6, no. 9, pp. 1249–1269.
7. Poprach A., Petrakova K., Vyskocil J. et al. Klin. Onkol. 2008, vol. 21, no. 5, pp. 288–293.
8. Sereno M., Brunello A., Chiappori A. et al. Clin. Transl. Oncol. 2008, vol. 10, no. 1, pp. 35–46.
9. Mikulyak N. I., Kinzirskaya Yu. A., Solomanina O. O., Ionicheva L. V. Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region.Meditsinskie nauki [University proceedings. Volga region. Medical sciences].2007,no.3,pp.10-17.
10. Anderson B., Sawyer D. B. Expert Rev. Cardiovasc. Ther. 2008, vol. 6, no. 7, pp. 1023–1033.
11. Pai V. B., Nahata M. C. Drug Saf. 2000, vol. 22, no. 4, pp. 263–302.
12. Mikulyak N. I., Kinzirskaya Yu. A. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta [Bulletin of Volgograd State Medical University]. 2011, no. 1, pp. 101–103.
13. Kharitonova E. A., Mikulyak N. I., Kinzirskaya Yu. A., Moiseeva I. Ya. Sovremennye naukoemkie tekhnologii [Modern science intensive technologies]. 2005, no. 4, pp. 61–62.
14. Anderson B., Sawyer D. B. Expert Rev. Cardiovasc. Ther. 2008, vol. 6 (7), pp. 1023–1033.
15. Mikulyak N. I., Mikulyak A. I., Gol'dkhaur S. A. Vestnik RUDN. Seriya «Meditsina» [Bulletin of Russian People’s Friendship University. Series “Medicine”.]. 2009, no. 6, pp. 762–765.
16. Solomanina O. O., Mikulyak N. I., Kinzirskiy A. S. Sovremennye naukoemkie tekhnologii [Modern science intensive technologies]. 2005, no. 6, pp. 41–42.
17. Gershanovich M. L. Voprosy onkologii [Problems of oncology]. 2001, vol. 47, no. 1, pp. 121–122.
18. Mikulyak N. I., Kinzirskaya Yu. A., Mikulyak A. I. Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region. Meditsinskie nauki [University proceedings. Volga region. Medical sciences]. 2009, no. 1 (9), pp. 89–101.
19. Solomanina O. O., Mikulyak N. I., Kinzirskiy A. S., Moiseeva I. Ya. Sovremennye naukoemkie tekhnologii [Modern science intensive technologies]. 2005, no. 4, pp. 59–60.